Sarcopenia during COVID-19 lockdown restrictions: long-term health effects of short-term muscle loss
Authors
Kirwan, Richard; orcid: 0000-0003-4645-0077; email: r.p.kirwan@2018.ljmu.ac.ukMcCullough, Deaglan; orcid: 0000-0002-9882-9639
Butler, Tom; orcid: 0000-0003-0818-1566; email: t.butler@chester.ac.uk
Perez de Heredia, Fatima; orcid: 0000-0002-2537-3327
Davies, Ian G.; orcid: 0000-0003-3722-8466
Stewart, Claire; orcid: 0000-0002-8104-4819
Publication Date
2020-10-01Submitted date
2020-06-25
Metadata
Show full item recordAbstract
Abstract: The COVID-19 pandemic is an extraordinary global emergency that has led to the implementation of unprecedented measures in order to stem the spread of the infection. Internationally, governments are enforcing measures such as travel bans, quarantine, isolation, and social distancing leading to an extended period of time at home. This has resulted in reductions in physical activity and changes in dietary intakes that have the potential to accelerate sarcopenia, a deterioration of muscle mass and function (more likely in older populations), as well as increases in body fat. These changes in body composition are associated with a number of chronic, lifestyle diseases including cardiovascular disease (CVD), diabetes, osteoporosis, frailty, cognitive decline, and depression. Furthermore, CVD, diabetes, and elevated body fat are associated with greater risk of COVID-19 infection and more severe symptomology, underscoring the importance of avoiding the development of such morbidities. Here we review mechanisms of sarcopenia and their relation to the current data on the effects of COVID-19 confinement on physical activity, dietary habits, sleep, and stress as well as extended bed rest due to COVID-19 hospitalization. The potential of these factors to lead to an increased likelihood of muscle loss and chronic disease will be discussed. By offering a number of home-based strategies including resistance exercise, higher protein intakes and supplementation, we can potentially guide public health authorities to avoid a lifestyle disease and rehabilitation crisis post-COVID-19. Such strategies may also serve as useful preventative measures for reducing the likelihood of sarcopenia in general and in the event of future periods of isolation.Citation
GeroScience, volume 42, issue 6, page 1547-1578Publisher
Springer International PublishingType
articleDescription
From Springer Nature via Jisc Publications RouterHistory: received 2020-06-25, accepted 2020-09-16, registration 2020-09-17, pub-electronic 2020-10-01, online 2020-10-01, pub-print 2020-12
Publication status: Published
Funder: Liverpool John Moores University
Collections
Related items
Showing items related by title, author, creator and subject.
-
Visualization for epidemiological modelling: challenges, solutions, reflections and recommendationsDykes, Jason; orcid: 0000-0002-8096-5763; email: j.dykes@city.ac.uk; Abdul-Rahman, Alfie; orcid: 0000-0002-6257-876X; Archambault, Daniel; Bach, Benjamin; orcid: 0000-0002-9201-7744; Borgo, Rita; orcid: 0000-0003-2875-6793; Chen, Min; orcid: 0000-0001-5320-5729; Enright, Jessica; Fang, Hui; Firat, Elif E.; orcid: 0000-0001-9497-7928; Freeman, Euan; orcid: 0000-0002-6586-6951; et al. (The Royal Society, 2022-08-15)We report on an ongoing collaboration between epidemiological modellers and visualization researchers by documenting and reflecting upon knowledge constructs—a series of ideas, approaches and methods taken from existing visualization research and practice—deployed and developed to support modelling of the COVID-19 pandemic. Structured independent commentary on these efforts is synthesized through iterative reflection to develop: evidence of the effectiveness and value of visualization in this context; open problems upon which the research communities may focus; guidance for future activity of this type and recommendations to safeguard the achievements and promote, advance, secure and prepare for future collaborations of this kind. In describing and comparing a series of related projects that were undertaken in unprecedented conditions, our hope is that this unique report, and its rich interactive supplementary materials, will guide the scientific community in embracing visualization in its observation, analysis and modelling of data as well as in disseminating findings. Equally we hope to encourage the visualization community to engage with impactful science in addressing its emerging data challenges. If we are successful, this showcase of activity may stimulate mutually beneficial engagement between communities with complementary expertise to address problems of significance in epidemiology and beyond. See https://ramp-vis.github.io/RAMPVIS-PhilTransA-Supplement/. This article is part of the theme issue ‘Technical challenges of modelling real-life epidemics and examples of overcoming these’.
-
New insights into Perrault syndrome, a clinically and genetically heterogeneous disorder.Faridi, Rabia; orcid: 0000-0001-7788-8755; Rea, Alessandro; orcid: 0000-0002-6204-846X; Fenollar-Ferrer, Cristina; orcid: 0000-0003-4953-8891; O'Keefe, Raymond T; orcid: 0000-0001-8764-1289; Gu, Shoujun; Munir, Zunaira; orcid: 0000-0003-3342-9658; Khan, Asma Ali; orcid: 0000-0002-0894-3439; Riazuddin, Sheikh; orcid: 0000-0001-6012-0192; Hoa, Michael; orcid: 0000-0001-7469-2909; Naz, Sadaf; orcid: 0000-0002-1912-0235; et al. (2021-08-02)Hearing loss and impaired fertility are common human disorders each with multiple genetic causes. Sometimes deafness and impaired fertility, which are the hallmarks of Perrault syndrome, co-occur in a person. Perrault syndrome is inherited as an autosomal recessive disorder characterized by bilateral mild to severe childhood sensorineural hearing loss with variable age of onset in both sexes and ovarian dysfunction in females who have a 46, XX karyotype. Since the initial clinical description of Perrault syndrome 70 years ago, the phenotype of some subjects may additionally involve developmental delay, intellectual deficit and other neurological disabilities, which can vary in severity in part dependent upon the genetic variants and the gene involved. Here, we review the molecular genetics and clinical phenotype of Perrault syndrome and focus on supporting evidence for the eight genes (CLPP, ERAL1, GGPS1, HARS2, HSD17B4, LARS2, RMND1, TWNK) associated with Perrault syndrome. Variants of these eight genes only account for approximately half of the individuals with clinical features of Perrault syndrome where the molecular genetic base remains under investigation. Additional environmental etiologies and novel Perrault disease-associated genes remain to be identified to account for unresolved cases. We also report a new genetic variant of CLPP, computational structural insight about CLPP and single cell RNAseq data for eight reported Perrault syndrome genes suggesting a common cellular pathophysiology for this disorder. Some unanswered questions are raised to kindle future research about Perrault syndrome. [Abstract copyright: © 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.]
-
Risk Governance of Emerging Technologies Demonstrated in Terms of its Applicability to Nanomaterials.Isigonis, Panagiotis; orcid: 0000-0002-8404-7708; Afantitis, Antreas; Antunes, Dalila; Bartonova, Alena; Beitollahi, Ali; Bohmer, Nils; Bouman, Evert; Chaudhry, Qasim; Cimpan, Mihaela Roxana; Cimpan, Emil; et al. (2020-07-23)Nanotechnologies have reached maturity and market penetration that require nano-specific changes in legislation and harmonization among legislation domains, such as the amendments to REACH for nanomaterials (NMs) which came into force in 2020. Thus, an assessment of the components and regulatory boundaries of NMs risk governance is timely, alongside related methods and tools, as part of the global efforts to optimise nanosafety and integrate it into product design processes, via Safe(r)-by-Design (SbD) concepts. This paper provides an overview of the state-of-the-art regarding risk governance of NMs and lays out the theoretical basis for the development and implementation of an effective, trustworthy and transparent risk governance framework for NMs. The proposed framework enables continuous integration of the evolving state of the science, leverages best practice from contiguous disciplines and facilitates responsive re-thinking of nanosafety governance to meet future needs. To achieve and operationalise such framework, a science-based Risk Governance Council (RGC) for NMs is being developed. The framework will provide a toolkit for independent NMs' risk governance and integrates needs and views of stakeholders. An extension of this framework to relevant advanced materials and emerging technologies is also envisaged, in view of future foundations of risk research in Europe and globally. [Abstract copyright: © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.]